Novocure Reports Promising Data

Novocure reported late Monday promising data from two phase 2 pilots evaluating Tumor Treating Fields in patients with recurrent ovarian cancer and advanced pancreatic cancer.

The oncology company said data from the phase 2 pilot PANOVA trial suggested that TTFields plus first-line chemotherapies nab-paclitaxel and gemcitabine may be safe and tolerable in patients with advanced pancreatic cancer. The data also suggested an improved one-year survival rate in patients who received the combined TTFields therapy compared to patients who received nab-paclitaxel and gemcitabine alone.

Novocure also noted that progression free survival and one-year survival rates were more than double in patients treated with TTFields plus first-line chemotherapies compared to those of nab-paclitaxel and gemcitabine-treated historical controls.

Leave a Comment